IP Library Granted Patent US 10,702,490
Granted Patent B1
US 10,702,490 · App. 16/677,379 · Granted Jul 7, 2020

Cysteine composition and injection

Inventors: Angela Sutterer (Chesterfield, MO); Jill Simpson (Chesterfield, MO); Gauthier Pouliquen (Ternay, FR); Alain Constancis (Lyons, FR); Pierre Danner (Francheville, FR)
Assignee: Avadel Legacy Pharmaceuticals, LLC
A61K31/198A61K9/0019A61K9/08A61P3/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,702,490
App. No.
16/677,379
Granted
Jul 7, 2020
Kind
B1
Abstract

Cysteine compositions comprising less than about 400 μg/L of aluminum. For example, solutions of cysteine comprising a pharmaceutically acceptable solvent, cysteine, and less than about 145 μg/L of aluminum, wherein the solution is devoid of visible particulate matter. Cysteine compositions described herein may be suitable for injection. For example, disclosed cysteine solutions may be provided intravenously to meet amino acid nutritional requirement in individuals receiving total parenteral nutrition. Also provided are processes for preparing cysteine compositions, and methods for providing cysteine to individuals in need thereof.

Claims (33)

1. A cysteine hydrochloride solution comprising about 40 mg/mL to about 60 mg/mL of cysteine hydrochloride and a pH from about 1.0 to about 1.5, wherein preparation of the cysteine hydrochloride solution comprises:

acidifying water to a pH from about 1.0 to about 1.5 to form acidified water;

dissolving about 40 mg to about 60 mg of cysteine hydrochloride per 1 mL of acidified water to form a solution; and

filling and sealing a container in which the solution is disposed under flow of an inert gas.

2. The cysteine hydrochloride solution of claim 1 , which is free of visible particulate matter.

3. The cysteine hydrochloride solution of claim 1 , which is free of visible particulate matter when stored for at least six months at 25° C. and 60% relative humidity.

4. The cysteine hydrochloride solution of claim 1 , which is free of visible particulate matter when stored for at least 12 months at 25° C. and 60% relative humidity.

5. The cysteine hydrochloride solution of claim 1 , which is free of visible particulate matter when stored for at least 18 months at 25° C. and 60% relative humidity.

6. The cysteine hydrochloride solution of claim 1 , which is free of visible particulate matter when stored for at least 24 months at 25° C. and 60% relative humidity.

7. The cysteine hydrochloride solution of claim 1 , which has a cystine content of less than about 1% by weight of the total cysteine present in the cysteine hydrochloride solution.

8. The cysteine hydrochloride solution of claim 1 , which has a dissolved oxygen content of less than 2 mg/L.

9. The cysteine hydrochloride solution of claim 1 , wherein the pH of the cysteine hydrochloride solution is from about 1.0 to about 1.4.

10. The cysteine hydrochloride solution of claim 1 , wherein the pH of the cysteine hydrochloride solution is from about 1.0 to about 1.3.

11. The cysteine hydrochloride solution of claim 1 , wherein the pH of the cysteine hydrochloride solution is from about 1.0 to about 1.2.

12. The cysteine hydrochloride solution of claim 1 , having an aluminum content of less than about 200 μg/L.

13. The cysteine hydrochloride solution of claim 1 , having an aluminum content of less than about 145 μg/L.

14. The cysteine hydrochloride solution of claim 1 , having an aluminum content of less than about 100 μg/L.

15. The cysteine hydrochloride solution of claim 1 , having an aluminum content of less than about 30 μg/L.

16. The cysteine hydrochloride solution of claim 1 , having an aluminum content of less than about 10 μg/L.

17. The cysteine hydrochloride solution of claim 1 , having an aluminum content from about 0 μg/L to about 100 μg/L.

18. The cysteine hydrochloride solution of claim 1 , having an aluminum content from about 0 μg/L to about 30 μg/L.

19. The cysteine hydrochloride solution of claim 1 , having an aluminum content of less than about 145 μg/L when stored for at least six months at 25° C. and 60% relative humidity.

20. The cysteine hydrochloride solution of claim 1 , having an aluminum content of less than about 145 μg/L when stored for at least 12 months at 25° C. and 60% relative humidity.

21. The cysteine hydrochloride solution of claim 1 , having an aluminum content of less than about 145 μg/L when stored for at least 18 months at 25° C. and 60% relative humidity.

22. The cysteine hydrochloride solution of claim 1 , having an aluminum content of less than about 145 μg/L when stored for at least 24 months at 25° C. and 60% relative humidity.

23. The cysteine hydrochloride solution of claim 1 , which comprises about 50 mg/mL of cysteine hydrochloride.

24. The cysteine hydrochloride solution of claim 1 , wherein the acidifying is performed under flow of an inert gas.

25. The cysteine hydrochloride solution of claim 1 , wherein the preparation of the cysteine hydrochloride solution further comprises sparging water with an inert gas to achieve a dissolved oxygen content of less than 2 mg/L in the water prior to the acidifying.

26. The cysteine hydrochloride solution of claim 1 , wherein the dissolving comprises stirring under flow of an inert gas.

27. The cysteine hydrochloride solution of claim 1 , wherein the preparation of the cysteine hydrochloride solution further comprises sterile filtering the solution prior to the filling and sealing.

28. The cysteine hydrochloride solution of claim 27 , wherein the sterile filtering comprises passing the solution through at least one 0.22 μm filter.

29. The cysteine hydrochloride solution of claim 1 , wherein the acidifying, the dissolving, and the filling and sealing are performed at ambient temperature.

30. The cysteine hydrochloride solution of claim 1 , wherein the container is a silica-lined glass vial.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Jul 2, 2021
From: AVADEL LEGACY PHARMACEUTICALS, LLC
To: EXELA STERILE MEDICINES LLC
Reel/Frame 056743/0745 →
SECURITY INTEREST Recorded Jun 30, 2021
From: EXELA HOLDINGS, INC.; EXELA PHARMA SCIENCES, LLC; EXELA PHARMSCI, INC.; EXELA STERILE MEDICINES LLC; EXELA STERILE PRODUCTS LLC; EXELA STERILE EQUIPMENT, LLC; EXELA ADVANCED STRATEGIES LLC; AGELEX, LLC; EXELA HEALTH SYSTEMS, LLC; EXELA INITIATIVES, LLC; EXELA INNOVATIONS, LLC
To: LIVE OAK BANKING COMPANY
Reel/Frame 056722/0250 →
SECURITY INTEREST Recorded Jun 30, 2021
From: EXELA HOLDINGS, INC.; EXELA PHARMA SCIENCES, LLC; EXELA PHARMSCI, INC.; EXELA STERILE MEDICINES LLC; EXELA STERILE PRODUCTS LLC; EXELA STERILE EQUIPMENT, LLC; EXELA ADVANCED STRATEGIES LLC; AGELEX, LLC; EXELA HEALTH SYSTEMS, LLC; EXELA INITIATIVES, LLC; EXELA INNOVATIONS, LLC
To: LIVE OAK BANKING COMPANY
Reel/Frame 056722/0188 →
SECURITY INTEREST Recorded Jul 1, 2020
From: EXELA STERILE MEDICINES LLC
To: AVADEL LEGACY PHARMACEUTICALS, LLC
Reel/Frame 053101/0559 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2020
From: AVADEL LEGACY PHARMACEUTICALS, LLC
To: EXELA STERILE MEDICINES LLC
Reel/Frame 053101/0505 →
SECURITY INTEREST Recorded Jul 1, 2020
From: EXELA STERILE MEDICINES LLC
To: DEERFIELD PRIVATE DESIGN FUND IV, L.P.
Reel/Frame 053101/0717 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2020
From: FLAMEL IRELAND LIMITED
To: AVADEL LEGACY PHARMACEUTICALS, LLC
Reel/Frame 051666/0724 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2019
From: SUTTERER, ANGELA; SIMPSON, JILL; POULIQUEN, GAUTHIER; CONSTANCIS, ALAIN; DANNER, PIERRE
To: FLAMEL IRELAND LIMITED
Reel/Frame 050992/0249 →